2015/08/30 Medigen Vaccine Biologics CO. (MVC) submitted request for seasoned equity offering on September 14th , and was approved by Taiwan Financial Supervisory Commission on September 23rd . MVC issued 20,000,000 new shares with par value of $10 TWD and pric

MVC's H7N9 Phase I/II clinical trial fulfills the funding requirement of Fast Track Clinical Trial Project and received 14.03 million TWD from Ministry of Economic Affairs.

BACK TO LIST
We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies. Our Privacy & Cookie Policy contains more information on such use and explains how to disable cookies.
Agree